Combination drug approach aims to tame immune attack after stem cell transplant

NCT ID NCT05443425

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests whether adding leflunomide to standard steroid therapy can safely control acute graft-versus-host disease (aGVHD) in people who have had a stem cell transplant for blood cancer. aGVHD occurs when donor immune cells attack the patient's own body. Leflunomide and steroids both suppress the immune system but work in different ways. The study enrolls adults with moderate to severe aGVHD and primarily monitors side effects and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Leflunomide (Arava) plus steroids
What this could lead to
If it works, this combination could offer a new way to control graft-versus-host disease, reducing the need for high-dose steroids and their side effects.
What could go wrong
This is a small, early-phase trial focused on safety, not yet proven to work. Leflunomide may cause side effects like liver problems or infections, and the combination may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.